跳至主要内容
临床试验/NCT04337255
NCT04337255进行中(未招募)不适用

MIND Diet and Dementia Prevention in Ischemic Stroke Patients

Rush University Medical Center2 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2021年12月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
250
试验地点
2
主要终点
Change in global cognitive score

研究概览

简要总结

To test the effects of a 2- to 3-year intervention of the MIND diet versus usual post-stroke care on cognitive decline, the characteristic feature of dementia, and on brain biomarkers of Alzheimer's Disease (AD) and vascular disease in a Phase Ill randomized controlled trial of 250 patients hospitalized for acute ischemic stroke, aged 55 years or older, and without dementia who are discharged home following hospitalization.

详细描述

The Mediterranean-DASH diet intervention for Neurodegenerative Delay (MIND in Stroke patients is designed to test the effects of a 2-3 year intervention of a hybrid of the Mediterranean and DASH diets, called MIND on 250 older patients, without dementia who are hospitalized for acute stroke who are discharged home following hospitalization. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetable and berries as well as food component servings that reflect the nutrition dementia evidence. In this study we will test the effects of a 2- to 3-year intervention of the MIND diet (3 months of delivered meals followed by dietary and general stroke health counseling) versus usual post-stroke care (3 months delivered self-selected meals followed by general stroke health counseling) on change on cognitive outcomes over 24 to 36 months. Biological effects of the MIND diet will be assessed by measurement of brain macro and microstructural integrity in all trial participants. Other biochemical markers will be assessed in the entire group of 250 participants including: plasma Abeta42/beta40, brain derived neurotropic factor (BDNF) and plasma markers of oxidative stress and inflammation. The trial will examine potential effect mediators and modifiers by a number of cardiovascular risk factors, AD biomarkers and biological mechanisms. The proposed study has 3 recruitment sites, Rush University Medical Center, University of Chicago, and Advocate Christ Hospital all located in Chicago.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

盲法说明

Single ( Outcomes assessor)

入排标准

年龄范围
55 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria
  • Men and women, 55 years of age - inclusive- or older
  • Acute stroke as defined by an acute focal neurological deficit in combination with one of the following: acute ischemic infarct (stroke) as documented by either a DWl positive lesion on MR imaging or a new lesion on a delayed CT scan
  • Written informed consent by patient prior to study participation
  • Willingness to complete all assessments and participate in follow-up
  • Willing to participate and give informed consent
  • Adequate Visual and auditory acuity to undergo neuropsychological testing

排除标准

  • CDR>=0.5
  • Nuts, berries, olive oil, or fish allergies
  • Use of medications to treat Alzheimer's disease or Parkinson's disease
  • Conditions of psychosis or bipolar disorder judged by study investigators to potentially interfere with study compliance over 3 years
  • Report of alcohol or substance abuse within six months, or heavy alcohol consumption (>2 drinks/d women; >3 drinks/d men)
  • Unstable or recent onset of cardiovascular disease, such as myocardial infarction within six months or presence of congestive heart failure (Stages II-IV)
  • Cancer treatment <= 5 years except non-melanoma skin cancer , basal cell skin cancer (this criterion may be waived at the site PI's discretion)
  • Illness that might be associated with weight change, such as a history of stomach or gastrointestinal conditions (Inflammatory Bowel Disease, Crohn's Disease, malabsorption, colostomy, bowel resection, gastric bypass surgery, etc.)
  • History of liver disease, HIV or Hepatitis C
  • An intracerebral hemorrhage as documented on CT or MRI
  • Pre- hospitalization diagnosis of dementia or mild cognitive impairment
  • Patients presenting one of the following diseases: cerebral venous thrombosis, traumatic cerebral hemorrhage, intracerebral hemorrhage because of a known or image-guided assumed vascular malformation, pure meningeal or intraventricular hemorrhage
  • Patients presenting a malignant disease with life expectancy < 3 years
  • Residence in a nursing home and thus going back to nursing home upon discharge
  • Participation in an ongoing investigational drug study
  • Exception to these guidelines will be rare but may be considered on a case by case basis at the discretion of the PI's

研究组 & 干预措施

MIND DIET intervention

Active Comparator

Allocation and blinding 3 year intervention of MIND Diet + counseling

干预措施: Behavioral Dietary intervention ( MIND Diet) (Other)

Usual care diet intervention

Placebo Comparator

3 year Intervention of usual care diet + counseling

干预措施: Behavioral Usual Care Diet Intervention (Other)

结局指标

主要结局

Change in global cognitive score

时间窗: 3-years

3-year change in global cognitive score. The global cognitive score is a composite score, based on the average of z scores of the 19 individual tests scores, with a mean of 0 and standard deviation of 1. Higher scores reflect high global cognitive function.

次要结局

  • Change in brain MRI derived markers of macro and micro structural integrity (cubic Centimeters), total brain volume, hippocampal volume and white matter hyperintensity volume ( cubic centimeters)(3-years)
  • Change in 5 individual cognitive domains(3-years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Neelum T. Aggarwal, MD

Principal Investigator

Rush University Medical Center

研究点 (2)

Loading locations...

相似试验

Mediterranean-DASH Intervention for... | 临床试验